Amedica Corp. entered into an agreement with Kyocera Industrial Ceramics Corp. to manufacture Amedica’s silicon nitride biomaterial at Kyocera’s Vancouver, Wash., facility.
The FDA-cleared silicon nitride has the potential to promote bone growth defend against infection. Devices made from silicon nitride are semi-radiolucent with clearly visible boundaries, enabling an exact view of intra-operative placement and postoperative fusion assessment via common imaging modalities, according to a press release.